ResearcherKyoto UniversityNo recent work listed
Tadayuki Kou
Matched on ORCID iD 0000-0001-6397-2446; OpenAlex author ID A5082519245. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper
Papers 4
- Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicente… Co-author DOI 10.1007/s12032-023-02011-y↗
- Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. Co-author DOI 10.18632/oncotarget.24865↗
- Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-015-0864-x↗
- Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis … First author DOI 10.1016/j.ejca.2015.11.002↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Manabu Muto · 3 shared papers, 2016–2023 · strength 0.25
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Toshihiko Masui · 3 shared papers, 2016–2023 · strength 0.25
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Masashi Kanai · 3 shared papers, 2016–2023 · strength 0.25
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Tomohiro Kondo · 2 shared papers, 2018–2023 · strength 0.21
- Paper Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced p… DOI 10.1007/s12032-023-02011-y↗
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Toshinao Itani · 1 shared paper, 2023 · strength 0.14
- Michio Yoshimura · 1 shared paper, 2023 · strength 0.14
- Junichi Matsubara · 1 shared paper, 2023 · strength 0.14
- Kyoichi Takaori · 2 shared papers, 2016–2018 · strength 0.11
- Paper Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. DOI 10.18632/oncotarget.24865↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Shujiro Yazumi · 2 shared papers, 2016 · strength 0.10
- Paper Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, … DOI 10.1016/j.ejca.2015.11.002↗
- Paper Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic canc… DOI 10.1007/s10147-015-0864-x↗
- Yuzo Kodama · 1 shared paper, 2018 · strength 0.07
- Nobumasa Mizuno · 1 shared paper, 2016 · strength 0.06
- Susumu Hijioka · 1 shared paper, 2016 · strength 0.06
- Shinichi Egawa · 1 shared paper, 2016 · strength 0.06
- Kazuo Hara · 1 shared paper, 2016 · strength 0.06
- Hiroshi Imaoka · 1 shared paper, 2016 · strength 0.06
- Masao Tanaka · 1 shared paper, 2016 · strength 0.06
- Kenji Yamao · 1 shared paper, 2016 · strength 0.06
- Tsutomu Chiba · 1 shared paper, 2016 · strength 0.04
- Shinji Üemoto · 1 shared paper, 2016 · strength 0.04
- Peng Xue · 1 shared paper, 2016 · strength 0.04
- Akira Kurita · 1 shared paper, 2016 · strength 0.04
- Yuzo Kodama · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.